STOCK TITAN
  1. Home
  2. Sec-filings
  3. FEED
  4. [8-K] ENvue Medical, Inc. Reports Material Event

ENvue Medical faces Nasdaq bid-price deficiency risk

ENvue Medical, Inc. received a Nasdaq Staff Determination Letter on July 10, 2026 stating that its common stock has failed to meet the Nasdaq Capital Market minimum bid price requirement.

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

ENvue Medical, Inc. received a Nasdaq Staff Determination Letter on July 10, 2026 stating that its common stock has failed to meet the Nasdaq Capital Market minimum bid price requirement. The closing bid price was below $1.00 per share for 30 consecutive business days from May 26, 2026 through July 8, 2026, violating Nasdaq Listing Rule 5550(a)(2).

Ordinarily the company would receive a 180-calendar day grace period, but under Nasdaq Listing Rule 5810(c)(3)(A)(iv) it is not eligible for any compliance period because it effected a 1-for-10 reverse stock split on August 12, 2025. ENvue Medical plans to request a hearing before a Nasdaq Hearings Panel under the Nasdaq Listing Rule 5800 Series, which will stay any suspension or delisting action while the appeal is pending. The company notes there is no assurance the Panel will grant continued listing or that it will regain and maintain compliance with the Minimum Bid Price Requirement and other Nasdaq standards.

Positive

  • None.

Negative

  • Nasdaq minimum bid price noncompliance without cure period after shares traded below $1.00 for 30 consecutive business days, increasing near-term delisting risk.

Insights

Nasdaq noncompliance with no grace period heightens delisting risk.

ENvue Medical has fallen below Nasdaq’s $1.00 minimum bid price for 30 consecutive business days, triggering a deficiency notice under Nasdaq Listing Rule 5550(a)(2). Because it completed a 1-for-10 reverse stock split on August 12, 2025, Nasdaq Listing Rule 5810(c)(3)(A)(iv) removes the usual 180-day cure period, immediately escalating the issue.

The company plans to request a hearing before a Nasdaq Hearings Panel under the Listing Rule 5800 Series. That request will stay any suspension or delisting action until the Panel issues a decision. The company explicitly warns there can be no assurance that the Panel will grant continued listing or that it will regain and maintain compliance with the Minimum Bid Price Requirement or other Nasdaq standards.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Minimum bid price threshold $1.00 per share Nasdaq Listing Rule 5550(a)(2) Minimum Bid Price Requirement for continued listing
Noncompliance trading period length 30 consecutive business days Closing bid price below $1.00 from May 26, 2026 through July 8, 2026
Typical compliance period 180-calendar day compliance period Ordinarily available under Nasdaq Listing Rule 5810(c)(3)(A) but not granted here
Reverse stock split ratio 1-for-10 Reverse stock split of common stock effected on August 12, 2025
Reverse stock split date August 12, 2025 Date ENvue Medical effected a 1-for-10 reverse stock split
Determination Letter date July 10, 2026 Date Nasdaq Listing Qualifications Staff issued the noncompliance notice
Minimum Bid Price Requirement regulatory
"not in compliance with the minimum bid price requirement for continued listing"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
reverse stock split financial
"the Company has effected a reverse stock split over the prior one-year period"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Nasdaq Listing Rule 5550(a)(2) regulatory
"set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”)"
Nasdaq Listing Rule 5810(c)(3)(A)(iv) regulatory
"pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Staff has determined"
Nasdaq Listing Rule 5800 Series regulatory
"request a hearing before the Panel to appeal the Staff’s determination"
NASDAQ Listing Rule 5800 Series is the set of exchange rules that governs how and why a company’s shares can be removed from NASDAQ, including the warning, hearing and appeal steps before delisting. Think of it like a landlord’s lease rules and eviction process for a building: they explain the specific conditions that can lead to removal and the formal steps a company must follow. Investors care because delisting can sharply reduce a stock’s visibility, trading ease and value, so these rules affect risk and liquidity.

FAQ

What Nasdaq issue did ENvue Medical (FEED) disclose on July 10, 2026?
ENvue Medical disclosed that Nasdaq determined the company is not in compliance with the $1.00 minimum bid price requirement after 30 consecutive business days below that level on the Nasdaq Capital Market.

Why doesn’t ENvue Medical (FEED) receive a 180-day grace period from Nasdaq?
Nasdaq cited Listing Rule 5810(c)(3)(A)(iv), which makes ENvue Medical ineligible for any bid-price compliance period because it effected a 1-for-10 reverse stock split within the prior one-year period.

What period triggered ENvue Medical’s (FEED) Nasdaq bid price deficiency?
Nasdaq found ENvue Medical noncompliant because its closing bid price was below $1.00 per share for 30 consecutive business days from May 26, 2026 through July 8, 2026 on the Nasdaq Capital Market.

How is ENvue Medical (FEED) responding to the Nasdaq delisting notice?
ENvue Medical intends to timely request a hearing before a Nasdaq Hearings Panel under the Listing Rule 5800 Series, which will stay any suspension or delisting action while the Panel considers the appeal.

Is there any assurance ENvue Medical (FEED) will remain listed on Nasdaq?
No. ENvue Medical states there can be no assurance that the Panel will grant continued listing or that the company will regain and maintain compliance with Nasdaq’s Minimum Bid Price Requirement and other standards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001326706 0001326706 2026-07-10 2026-07-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 10, 2026

 

ENvue Medical, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36445   01-0801232

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

969 Pruitt Ave

Tyler, Texas

   77569
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (914) 233-3004

 

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $0.001 per share   FEED   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On July 10, 2026, ENvue Medical, Inc. (the “Company”) received a letter (the “Staff Determination Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined that the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), has been below $1.00 per share for the previous 30 consecutive business days (from May 26, 2026 through July 8, 2026) and, as a result, the Company is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

 

Ordinarily, a company that fails to meet the Minimum Bid Price Requirement would be afforded a 180-calendar day compliance period pursuant to Nasdaq Listing Rule 5810(c)(3)(A) to regain compliance. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Staff has determined that the Company is not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A), because the Company has effected a reverse stock split over the prior one-year period. As previously disclosed, the Company effected a 1-for-10 reverse stock split of the Common Stock on August 12, 2025.

 

The Company intends to timely request a hearing before the Panel to appeal the Staff’s determination, in accordance with the procedures set forth in the Nasdaq Listing Rule 5800 Series. A timely request for a hearing will stay any suspension or delisting action pending the Panel’s decision. There can be no assurance that the Company’s request for continued listing will be granted or that the Company will be able to regain and maintain compliance with the Minimum Bid Price Requirement or all other applicable requirements for continued listing on The Nasdaq Capital Market.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding the Company’s intent to request a hearing before the Panel, the Company’s ability to regain and maintain compliance with the Minimum Bid Price Requirement and other applicable Nasdaq continued listing requirements, and the outcome of any Panel hearing. Forward-looking statements are subject to a number of risks and uncertainties, including that the Panel may deny the Company’s request for continued listing or condition continued listing on requirements that the Company may not be able to satisfy, that the Company may not regain compliance with the Minimum Bid Price Requirement, and other risks and uncertainties set forth from time to time in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ENVUE MEDICAL, Inc.
     
Date: July 10, 2026 By: /s/ Doron Besser, M.D.
  Name: Doron Besser, M.D.
  Title: Chief Executive Officer

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents